Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in Chronic Primary ITP
NCT06004856Phase 3Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in primary immune thrombocytopenia (ITP), sponsored by InnoCare Pharma. Started Oct 2023; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06004856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004856.